Stock Research: AstraZeneca

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

AstraZeneca

LSE:AZN GB0009895292
43
  • Value
    49
  • Growth
    49
  • Safety
    Safety
    13
  • Combined
    13
  • Sentiment
    70
  • 360° View
    360° View
    43
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

AstraZeneca PLC is a biopharmaceutical company that discovers, develops, and commercializes prescription medicines. It operates in oncology, rare diseases, and biopharmaceuticals. In the last fiscal year, the company had a market cap of $216,842 million, profits of $44,415 million, revenue of $54,073 million, and 94,300 employees.

more
Index
FTSE All Shares
FTSE 100
FTSE 350
NASDAQ
OMX 30
Renewables Users
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
49 46 43 60
Growth
49 48 73 81
Safety
Safety
13 7 10 47
Sentiment
70 45 88 90
360° View
360° View
43 23 53 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
74 69 78 67
Opinions Change
24 19 52 52
Pro Holdings
n/a 87 92 80
Market Pulse
49 35 35 59
Sentiment
70 45 88 90
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
49 46 43 60
Growth
49 48 73 81
Safety Safety
13 7 10 47
Combined
13 15 28 70
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
42 26 28 44
Price vs. Earnings (P/E)
47 51 51 58
Price vs. Book (P/B)
24 18 15 34
Dividend Yield
64 71 74 70
Value
49 46 43 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
48 55 67 76
Profit Growth
62 42 60 74
Capital Growth
25 37 64 53
Stock Returns
47 67 42 68
Growth
49 48 73 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
24 20 20 9
Refinancing
8 6 7 96
Liquidity
49 54 44 32
Safety Safety
13 7 10 47

Similar Stocks

Discover high‑ranked alternatives to AstraZeneca and broaden your portfolio horizons.

Krka

LJU:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Metlen Energy & Metals

LSE:MTLN
Country: United Kingdom
Industry: Industrial Conglomerates
Size: Large
Full Stock Analysis

Vodafone

LSE:VOD
Country: United Kingdom
Industry: Wireless Telecommunication
Size: XX-Large
Full Stock Analysis

Smith & Nephew

LSE:SN.
Country: United Kingdom
Industry: Health Care Equipment
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: